Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxytetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.70 |
| ▸ | MEN1 | O00255 | 9/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.70 |
| ▸ | USP2 | O75604 | 7/20 | 0.70 |
| ▸ | HPGD | P15428 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | RECQL | P46063 | 5/20 | 0.70 |
| ▸ | THRB | P10828 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytetracycline SCHEMBL2899 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782519 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782617 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL18048891 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL2614977 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782467 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL1292896 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL21133474 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL21133472 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782478 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20090118269-A1 | Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20080312193-A1 | Substituted Tetracycline Compounds for Treatment of Inflammatory Skin Disorders | PARATEK PHARMACEUTICALS, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080287401-A1 | Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080118979-A1 | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080070873-A1 | Methods of increasing oral bioavailability of tetracyclines | PARATEK PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-7326696-B2 | Amino-methyl substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20080015169-A1 | Amino-methyl substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080003208-A1 | Creatine-ligand compounds and methods of use thereof | AVICENA FROUP, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | AVICENA GROUP, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | AVICENA GROUP, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118269-A1 | Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds | SMN1; SMN2, MTPN, TUBB2A | TDP1 586/4885MEN1 3088/4885KMT2A 1229/4885 |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | TDP1 999/4885MEN1 4065/4885KMT2A 634/4885 |
| US-20080312193-A1 | Substituted Tetracycline Compounds for Treatment of Inflammatory Skin Disorders | CUTA, KRT18, COL2A1 | TDP1 2132/4885MEN1 4627/4885KMT2A 2196/4885 |
| US-20080015169-A1 | Amino-methyl substituted tetracycline compounds | TET3, TET1, TPMT | TDP1 951/4885MEN1 1950/4885KMT2A 250/4885 |
| US-20080287401-A1 | Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds | NPEPPS, AAAS, AADAC | TDP1 1642/4885MEN1 3964/4885KMT2A 1064/4885 |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | MYC, TET1, TET3 | TDP1 2913/4885MEN1 2648/4885KMT2A 1255/4885 |
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | TET1, TET3, MYC | TDP1 2522/4885MEN1 1281/4885KMT2A 857/4885 |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | CKMT1A; CKMT1B, HTT, NLN | TDP1 469/4885MEN1 3422/4885KMT2A 478/4885 |
| US-20080003208-A1 | Creatine-ligand compounds and methods of use thereof | CKMT1A; CKMT1B, TARDBP, SLC7A11 | TDP1 556/4885MEN1 4797/4885KMT2A 1522/4885 |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | TDP1 1003/4885MEN1 3697/4885KMT2A 3257/4885 |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, DHFR | TDP1 1297/4885MEN1 2384/4885KMT2A 1153/4885 |
| US-20080070873-A1 | Methods of increasing oral bioavailability of tetracyclines | DHFR, SI, SLC10A2 | TDP1 1037/4885MEN1 3079/4885KMT2A 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.